Anti-infective hydroxy-phenyl-benzoates and methods of use
View Patent ↗The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analogue. The extracellular microorganism can be of the bacterial genus Staphylococcus , for example, Staphylococcus aureus . The extracellular microorganism can be a strain that is resistant to at least one antibiotic. The strain can be selected from the group consisting of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA). The invention also provides a method for preventing or treating an infectious disease caused by of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) or vancomycin-resistant Staphylococcus aureus (VRSA), comprising systemically coadministering in a synergistic combination to a subject in need thereof prophylactically or therapeutically effective amounts, individually or collectively, of a salicylic acid (SAL) or a SAL analogue and at least one additional antimicrobial agent, for example, vancomycin and/or linezolid.
1. A method for preventing or treating an infection caused by a microorganism, said method comprising systemically administering to a subject in need thereof a therapeutically effective amount of a salicylic acid (SAL) analogue comprising one or more halogenated phenyl moieties, wherein said subject has an infection caused by a microorganism.
2. The method of claim 1 , wherein the microorganism is a species of the bacterial genus Staphylococcus.
3. The method of claim 2 , wherein said species is Staphylococcus aureus.
4. The method of claim 1 , wherein said microorganism is a strain that is resistant to at least one antibiotic.
5. The method of claim 4 , wherein said strain is methicillin-resistant Staphylococcus aureus (MRSA).
6. The method of claim 1 , wherein said SAL analogue is Diflunisal.
7. A method for preventing or treating an infection caused by methicillin-resistant Staphylococcus aureus (MRSA), comprising systemically co-administering to a subject in need thereof therapeutically effective amounts of a salicylic acid (SAL) analogue comprising one or more halogenated phenyl moieties and at least one additional antimicrobial agent, where said SAL analogue and said at least one additional antimicrobial agent are co-administered individually or collectively, and wherein said subject has an infection caused by MRSA.
8. The method of claim 7 , wherein said additional antimicrobial agent is vancomycin, daptomycin or linezolid.
9. The method of claim 7 , wherein said SAL analogue is Diflunisal.
10. A method for preventing or treating an infection caused by vancomycin-resistant enterococci (VRE), comprising systemically co-administering to a subject in need thereof therapeutically effective amounts of a salicylic acid (SAL) analogue comprising one or more halogenated phenyl moieties and at least one additional antimicrobial agent, where said SAL analogue and said at least one additional antimicrobial agent are co-administered individually or collectively, and wherein said subject has an infection caused by VRE.
11. The method of claim 10 , wherein said additional antimicrobial agent is linezolid.
12. The method of claim 10 , wherein said SAL analogue is Diflunisal.
13. The method of claim 5 , wherein said MRSA stain is vancomycin susceptible (VSSA), vancomycin-intermediate susceptible (VISA) or vancomycin-resistant (VRSA).
14. The method of claim 1 , wherein said infection is an acute infection.
15. The method of claim 7 , wherein said infection is an acute infection.
16. The method of claim 10 , wherein said infection is an acute infection.